First Opioid Lawsuit Targeting Pharmacy Benefit Managers

Share this content:
First Opioid Lawsuit Targeting Pharmacy Benefit Managers
First Opioid Lawsuit Targeting Pharmacy Benefit Managers

THURSDAY, April 19, 2018 (HealthDay News) -- A first opioid lawsuit is targeting pharmacy benefit managers (PBMs), according to a report published in Managed Healthcare Executive.

Noting that until now, PBMs have not been sued for the opioid crisis, in February, a south Texas county included the three largest PBMs in a nationwide lawsuit, which focused on the opioid epidemic. Their inclusion was due to their role in allowing access to prescription opioids.

PBMs are not expected to question physician's therapeutic choice and do not have the same professional obligations as pharmacists do. However, they do have a lot of power, acting as the middlemen between doctor, patient, and pharmacy. They also have the most to gain from the cost of a prescription. PBMs are likely to be increasingly targeted in litigation. Health plans are contracting with PBMs for the benefit of patients, and as such, the PBMs have a responsibility to protect patients from harm. Allegations are likely to be that PBMs allowed a greater amount of opioids to be permitted in communities than could be supported based on the legitimate medical needs of the community.

"While it takes some creativity to do something new (like looking at PBMs) as a responsible party, my hunch is that other lawyers are likely to learn from this and will be interested in a potential additional source of settlement funds," Harry Nelson, from Nelson Hardiman, LLP, a health care law firm, said in the article.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »